Biocept's cnside™ cerebrospinal fluid assay featured in two oral presentations at the 2023 sno/asco cns cancer conference

San diego--(business wire)---- $bioc #csf--biocept, inc. (nasdaq: bioc) (“biocept” or the “company”), a leading provider of molecular diagnostic assays, products and services, announces that its cnside cerebrospinal fluid assay was featured in two oral presentations at the 2023 sno/asco cns cancer conference on saturday, august 12. the abstracts were presented by priya u. kumthekar, md, a united counsel for neurologic subspecialties (ucns)-certified neuro-oncologist at northwestern university, and david picci.
BIOC Ratings Summary
BIOC Quant Ranking